Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 611

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 611
---
 an initial determination of the competitiveness of total direct compensation for each executive officer to align the cash and equity compensation of our executive officers with the 50thto 75thpercentile as compared to our peer group.New Semnur is currently negotiating the terms of new employment agreements with the individuals that are expected to become the executive officers of New Semnur (the effectiveness of which will be subject to the successful closing of the Business Combination) and it is currently anticipated that, upon the closing of the Business Combination, and based upon the information provided by Compensia and external public resources available to New Semnur, the New Semnur Board will approve the following base salaries, target bonuses on terms and conditions to be determined by the New Semnur Board, the payment of which shall not commence until such time as the Oramed Note has been repaid in full or Oramed has otherwise consented to such compensation arrangements:SalaryTarget BonusJaisim Shah$1,100,000150%Henry Ji, Ph.D.$1,100,000150%Stephen Ma$345,00060%373
SEMNUR’S DIRECTOR COMPENSATION Semnur’s directors during the year ended December 31, 2024 are Dr. Ji and Mr. Shah, Semnur’s Chief Executive Officer and President. Neither Dr. Ji nor Mr. Shah received any compensation for their service as directors of Semnur during such time. New Semnur Director Compensation Following the Business Combination It is currently anticipated that, upon the closing of the Business Combination, the New Semnur Board will approve the following compensation for New Semnur’s non-employeedirectors:

| Annual Cash Compensation                                                                                 |     | Amount |        |
|:---------------------------------------------------------------------------------------------------------|:----|:-------|-------:|
| Board Members                                                                                            |     | $      | 82,500 |
| Chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee  |     | $      | 37,500 |
| Members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee |     | $      | 15,000 |

| Equity Compensation   |     | Number |         |
| Initial Stock Options |     |        | 250,000 |
| Annual Stock Options  |     |        | 100,000 |

All annual cash compensation amounts for New Semnur’s non-employee directorsare expected to be payable in equal quarterly installments in arrears, following